文献速递浆细胞疾病

淋巴细胞减少预测新诊断多发性骨髓瘤患者的不良结局

Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma.
PubMed 文献 · Blood Adv · 2025-01-01

该回顾性研究纳入2000至2019年间在退伍军人管理局医院诊断的11427例多发性骨髓瘤患者,按诊断时及此后至多2.5年的外周血绝对淋巴细胞计数(ALC)分为严重低下、低下和正常三组。诊断时淋巴细胞减少见于53%的患者,并与较差的总生存期(OS)相关;治疗和随访期间持续或新发淋巴细胞减少也与较差OS相关。作者认为ALC可作为多发性骨髓瘤风险分层的生物标志物。

要点

  • 诊断时ALC严重低下、低下和正常患者的中位OS分别为2.7、3.3和4.2年(P < .001)。
  • 诊断时淋巴细胞减少(包括严重低下和低下)见于53%的患者,并与较差OS相关。
  • 治疗和随访期间持续或新发淋巴细胞减少也与较差OS相关。

核心结论

  • 研究结果支持使用外周血绝对淋巴细胞计数(ALC)作为多发性骨髓瘤风险分层的生物标志物。

研究设计与样本

  • 回顾性评估2000年至2019年间在退伍军人管理局医院诊断的11427例多发性骨髓瘤患者,使用最接近诊断时及此后至多2.5年的ALC。
  • 按ALC分为三组:严重低下(<1 × 103/μL)、低下(1 × 103/μL至1.5 × 103/μL)和正常(>1.5 × 103/μL)。

主要发现

  • 诊断时淋巴细胞减少(包括严重低下和低下ALC)见于53%的患者,并与较差的总生存期(OS)相关。
  • 诊断时ALC严重低下、低下和正常患者的中位OS分别为2.7年、3.3年和4.2年(P < .001)。
  • 治疗和随访期间持续或新发淋巴细胞减少也与较差OS相关。

关键数值与推荐

  • ALC分组阈值:严重低下<1 × 103/μL,低下1 × 103/μL至1.5 × 103/μL,正常>1.5 × 103/μL。
  • 诊断时ALC严重低下、低下和正常患者的中位OS分别为2.7年、3.3年和4.2年(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone marrow microenvironment plays an important role in promoting growth and survival of multiple myeloma (MM) cells. The tumor-promoting immune microenvironment is augmented while antitumor immune responses are inhibited. Although clinical and genomic markers of high-risk MM have been described, the immune status is just being recognized as a potential mediator of disease behavior. This is even more important with the development of a number of immune-based therapies. Based on these considerations, we evaluated peripheral blood absolute lymphocyte count (ALC) as an easily accessible marker representing immune microenvironment at diagnosis and after treatment of MM. We retrospectively evaluated 11 427 patients diagnosed with MM between 2000 and 2019 at Veterans Administration hospitals using ALC obtained closest to diagnosis and up to 2.5 years thereafter. Patients were stratified into 3 ALC categories: severely low, low, and normal (<1 × 103/μL, 1 × 103/μL to 1.5 × 103/μL, and >1.5 × 103/μL, respectively). Lymphopenia (including severely low and low ALC) was present in 53% of patients at MM diagnosis and was associated with inferior overall survival (OS). The median OS for patients with severely low, low, and normal ALC at diagnosis was 2.7, 3.3, and 4.2 years (P < .001), respectively. Moreover, persistent or new development of lymphopenia during treatment and follow-up was also associated with inferior OS. Our findings support the use of ALC as a biomarker for risk stratification in MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ferri GM, Yildirim C, Do NV, et al. Lymphopenia predicts poor outcomes in newly diagnosed multiple myeloma. Blood Adv. 2025. PMID: 39471425. doi:10.1182/bloodadvances.2024014125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。